

# RISK: Health, Safety & Environment (1990-2002)

---

Volume 7  
Number 3 *Symposium: Promoting and  
Managing Genome Innovation*

Article 2

---

June 1996

## Table of Contents Volume Seven, Number Three, Summer 1996

RISK Editorial Board

Follow this and additional works at: <https://scholars.unh.edu/risk>



Part of the [Law Commons](#), [Life Sciences Commons](#), [Physical Sciences and Mathematics Commons](#),  
and the [Social and Behavioral Sciences Commons](#)

---

### Repository Citation

Risk Editorial Board, *Table of Contents Volume Seven, Number Three, Summer 1996*, 7 RISK [vii] (1996).

This Prefatory Matter is brought to you for free and open access by the University of New Hampshire – Franklin Pierce School of Law at University of New Hampshire Scholars' Repository. It has been accepted for inclusion in RISK: Health, Safety & Environment (1990-2002) by an authorized editor of University of New Hampshire Scholars' Repository. For more information, please contact [ellen.phillips@law.unh.edu](mailto:ellen.phillips@law.unh.edu).

# RISK

Health, Safety & Environment

Volume 7

1996

Number 3

## Symposium: Promoting and Managing Genome Innovation

Suzanne A. Sprunger & Gianna Julian-Arnold, <i>Introduction</i>	197
Elaine Alma Draper, <i>Social Issues of Genome Innovation and Intellectual Property</i>	
Dr. Draper's focus is the use of personal information derived from genome research. She identifies several potential problems, including access to and control of genetic information, employment discrimination and social stratification. She also recommends possible solutions.	201
Kate H. Murashige, <i>Genome Research and Traditional Intellectual Property Protection — A Bad Fit?</i>	
Dr. Murashige addresses the need for a patent system more closely tailored to the needs of biotechnology. For example, the obviousness requirement may interfere with using patents to recoup high costs of work when it could arguably be done by researchers of ordinary skill.	231
Phillip K. Russell, <i>Development of Vaccines to Meet Public Health Needs: Incentives and Obstacles</i>	
Dr. Russell explains how such matters as high costs of regulation, lack of an effective plan for delivery (particularly abroad) and politics can interfere with providing globally needed vaccines.	239
Brian C. Cunningham, <i>Impact of the Human Genome Project at the Interface between Patent and FDA Laws</i>	
Mr. Cunningham stresses the broad scope of biotechnological innovations. Besides endorsing the need for a new oversight commission to deal with potential social issues, he suggests, for example, that some products should be treated like biologics rather than new drugs.	253

Jeffrey N. Gibbs, *The Human Genome, FDA and Product Liability*

Mr. Gibbs describes the risks to innovators associated with FDA regulations. He also points out how developers and marketers of products based on human genome research face such risks both before and after marketing.

267

Susan J. Timian & D. Michael Connolly, *The Regulation and Development of Bioremediation*

The authors describe how federal statutes regulating hazardous wastes create both incentives and disincentives for exploiting the large potential of bioremediation. Ultimately, they argue for regulation attending more to comparative risks and costs.

279

---

### Meeting Announcements

---

#### Florida Managed Care Conference

First Meeting of the Florida Managed Care Institute

September 9–11, 1996; Orlando FL

Contact Lorry Davis, FMCI Program Planner, 3807 NW 53d Terr, Gainesville FL 32606. Phone (352) 372-9360; fax 373-8034.

#### Assessing the Risks of Adverse Endocrine-Mediated Risks

International Society of Regulatory Toxicology & Pharmacology

January 13–14, 1997; Research Triangle Park NC

Contact C. Jellef Carr, Secretary ISRTP, 6546 Bellview, Columbia MD 21046. Phone (410) 992-9083; fax 740-9181.

#### First Biannual International Meeting

Risk Assessment & Policy Association

March 6–7, 1997; Alexandria VA

Contact Carol Ruh, Asst. Secretary-Treasurer, RAPA — see inside front cover, this issue.

---

### Correction

Please note the *italicized omission* from a sentence, at 6 Risk 346: Preferences involving value hierarchy, H, have property, P, involving preferences (with or without uncertainty) *if, and only if*, aggregation function  $f_H$  using weights  $w_1, \dots, w_n$  has convenient property  $F_p$ , e.g., linear, multilinear or multiplicative.